You deserve tomorrow.

Dosage Forms

Mayne Pharma chooses to develop generic and branded products that have limited competition and/or intrinsic barriers to entry:

  • Schedule II-V controlled substances
  • Modified-release
  • Inherently unstable active pharmaceuticals ingredients (APIs)
  • Limited access APIs
  • Highly potent APIs
  • Paragraph IV challenges
  • APIs with poor bioavailability

Our portfolio and pipeline focuses on the following dosage forms:

  • Modified-release tablets and capsules
  • Immediate-release tablets and capsules
  • Powders
  • Semi-solids
  • Solutions

In addition to the above, Mayne Pharma continually seeks to expand its technological capabilities into new dosage forms and delivery systems.